Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2012, vol. 21, nr 6, November-December, p. 751–757

Publication type: original article

Language: English

A High-Carbohydrate Diet Effects on the A Allele of Hepatic Lipase Polymorphism on the apoB100/apoAI Ratio in Young Chinese Males

Wpływ wysokowęglowodanowej diety i allelu A polimorfizmu lipazy wątrobowej na wskaźnik apoB100/apoAI u młodych Chińczyków

Minshan Hu1,A,B,C,D,E, Zhengke Li1,B,C, Ding Zhi Fang1,A,C,E,F

1 Department of Biochemistry and Molecular Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, China

Abstract

Background. Diet induces changes in plasma lipid profiles, and the plasma lipid profiles vary among different genetic backgrounds.
Objectives. The aim of this study was to investigate how a high-carbohydrate (high-CHO) diet interacts with hepatic lipase G-250A promoter polymorphism to affect the ratios of plasma lipids and apolipoproteins (apo) in a young Chinese population.
Material and Methods. Experiments were conducted on 56 university students. A stabilization diet was given for 7 days and a high-CHO diet was followed for 6 days. The diets used in this study were described by Song et al. and the following parameters were evaluated: total plasma triglyceride (TG), total plasma cholesterol (TC), plasma high-density lipoprotein cholesterol (HDL-C), plasma low-density lipoprotein cholesterol (LDL-C), apoB100 and apoAI. The plasma lipid and apoB100/apoAI ratios were also calculated and hepatic lipase G-250A polymorphism was analyzed.
Results. At baseline, no significant difference was detected for subjects with different genotypes and genders. All the parameters showed significant differences before and after the high-CHO diet, and these differences are gender-specific: after the high-CHO diet, the TG/HDL-C ratios significantly increased in females (GG genotype: P = 0.004; A carriers: P = 0.005). The TC/HDL-C ratios significantly decreased in GG genotype males (P = 0.007), A carrier males (P < 0.0001) and A carrier females (P = 0.016) and the LDL-C/HDL-C ratios significantly decreased in the GG genotype males (P = 0.011), A carrier males (P < 0.0001) and A carrier females (P = 0.001). However, comparing the apoB100/apoAI ratio before and after the high-CHO diet, a significant difference only existed in male A carriers (P = 0.009).
Conclusion. The results of this study show that the high-CHO diet induces the positive effects on the lipid ratios in general, only except the TG/HDL-C ratio in females. Noticeably, the decreased apoB100/apoAI ratio is associated with the A allele of hepatic lipase G-250A polymorphism only in young Chinese males.

Streszczenie

Wprowadzenie. Dieta wywołuje zmiany w profilu lipidów w osoczu, a profile lipidów w osoczu różnią się w zależności od tła genetycznego.
Cel pracy. Zbadanie, jak wysokowęglowodanowa dieta oddziałuje na polimorfizm promotora G-250A lipazy w wątrobie i wpływa na iloraz lipidów w osoczu i apolipoprotein (APO) w młodej populacji chińskiej.
Materiał i metody. Badania przeprowadzono na 56 studentach. Dietę stabilizacyjną podawano przez 7 dni, a wysokowęglowodanową przez następne 6 dni. Diety użyte w tym badaniu opisali Song et al. Oceniano następujące wskaźniki: triglicerydy całkowite w osoczu (TG), całkowity cholesterol w osoczu (TC), lipoproteiny o dużej gęstości w osoczu (LDL-C), lipoproteiny o małej gęstości (LDL-C), apoAI i apoB100. Obliczono również lipidy w osoczu i wskaźnik apoB100/apoAI. Analizowano polimorfizm G-250A lipazy w wątrobie.
Wyniki. Na początku badania nie stwierdzono istotnych różnic u osób z różnymi genotypami i różnej płci. Wszystkie parametry istotnie zmieniły się po zastosowaniu diety wysokowęglowodanowej, a różnice te są związane z płcią: po zastosowaniu diety wysokowęglowodanowej, wskaźnik TG / HDL-C znacznie zwiększył się u kobiet (genotyp GG: P = 0,004; nośniki: P = 0,005). Wskaźnik TC / HDL-C znacznie zmniejszył się u mężczyzn z genotypem GG (P = 0,007), u mężczyzn nośników A (p <0,0001) i kobiet nośników A (p = 0,016), a wskaźniki LDL-C/HDL-C znacząco zmniejszyły się u mężczyzn z genotypem GG (p = 0,011), u mężczyzn nośników A (p < 0,0001) i kobiet nośników A (P = 0,001). Porównując współczynnik apoB100/apoAI przed i po zastosowaniu diety wysokowęglowodanowej, istnieje znacząca różnica tylko), u mężczyzn nośników A (p = 0,009).
Wnioski. Wyniki tego badania wskazują, że wysokowęglowodanowa dieta ma korzystny wpływ na wskaźniki lipidów w ogóle, z wyjątkiem TG / HDL-C u kobiet. Warto zauważyć, że zmniejszenie ilorazu apoB100/apoAI jest związane z allelem A polimorfizmu G-250A lipazy w wątrobie tylko u młodych mężczyzn pochodzenia chińskiego.

Key words

diet, dyslipidemia, hepatic lipase, cardiovascular diseases

Słowa kluczowe

dieta, dyslipidemia, lipaza wątroby, choroby układu krążenia

References (26)

  1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the interheart study): Case-control study. Lancet 2004, 364, 937–952.
  2. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106, 3143–3421.
  3. Kastelein JJ, Van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM: Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008, 117, 3002–3009.
  4. Hsia SH, Pan D, Berookim P, Lee ML: A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol 2006, 98, 1047–1052.
  5. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S: Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the interheart study): A case-control study. Lancet 2008, 372, 224–233.
  6. Kasim-Karakas SE, Almario RU, Mueller WM, Peerson J: Changes in plasma lipoproteins during low-fat, highcarbohydrate diets: Effects of energy intake. Am J Clin Nutr 2000, 71, 1439–1447.
  7. Satoh H, Nishino T, Tomita K, Tsutsui H: Fasting triglyceride is a significant risk factor for coronary artery disease in middle-aged Japanese men. Circ J 2006, 70, 227–231.
  8. Takata Y Maskarinec G, Franke A, Nagata C, Shimizu H: A comparison of dietary habits among women in Japan and Hawaii. Public Health Nutr 2004, 7, 319–326.
  9. Chen Z, Shu XO, Yang G, Li H, Li Q, Gao YT, Zheng W: Nutrient intake among Chinese women living in Shanghai, China. Br J Nutr 2006, 96, 393–399.
  10. Ehnholm C, Kuusi T: Preparation, characterization, and measurement of hepatic lipase. Methods Enzymol 1986, 129, 716–738.
  11. Kounnas MZ, Chappell DA, Wong H, Argraves WS, Strickland DK: The cellular internalization and degradation of hepatic lipase is mediated by low density lipoprotein receptor-related protein and requires cell surface proteoglycans. J Biol Chem 1995, 270, 9307–9312.
  12. Applebaum-Bowden D: Lipases and lecithin: Cholesterol acyltransferase in the control of lipoprotein metabolism. Curr Opin Lipidol 1995, 6, 130–135.
  13. Kadowaki H, Patton GM, Robins SJ: Metabolism of high density lipoprotein lipids by the rat liver: Evidence for participation of hepatic lipase in the uptake of cholesteryl ester. J Lipid Res 1992, 33, 1689–1698.
  14. Ameis D, Stahnke G, Kobayashi J, McLean J, Lee G, Buscher M, Schotz MC, Will H: Isolation and characterization of the human hepatic lipase gene. J Biol Chem 1990, 265, 6552–6555.
  15. Van’t Hooft FM, Lundahl B, Ragogna F, Karpe F, Olivecrona G, Hamsten A: Functional characterization of 4 polymorphisms in promoter region of hepatic lipase gene. Arterioscler Thromb Vasc Biol 2000, 20, 1335–1339.
  16. Zhao SP, Xie XZ, Nie S: The –250 G > A polymorphism in the human hepatic lipase gene promoter affects blood lipids in Chinese. Clin Chim Acta 2006, 365, 149–152.
  17. Eller P, Schgoer W, Mueller T, Tancevski I, Wehinger A, Ulmer H, Foeger B, Haltmayer M, Ritsch A, Patsch JR: Hepatic lipase polymorphism and increased risk of peripheral arterial disease. J Intern Med 2005, 258, 344–348.
  18. Pieters M, Vorster HH: Nutrition and hemostasis: A focus on urbanization in south Africa. Mol Nutr Food Res 2008, 52, 164–172.
  19. Song YY, Gong RR, Zhang Z, Li YH, Xiao LY, Zhou XD, Fang DZ: A high-carbohydrate diet enhances the adverse effect of the S2 allele of APOC3 SstI polymorphism on the TG/HDL-C ratio only in young Chinese females. Braz J Med Biol Res 2011, 44, 524–530.
  20. Meng L, Ruixing Y, Yiyang L, Xingjiang L, Kela L, Wanying L, Lin Z, Weixiong L, Dezhai Y, Shangling P: Association of LIPC –250 G > A polymorphism and several environmental factors with plasma lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis 2010, 9, 28.
  21. Santamarina-Fojo S, Haudenschild C, Amar M: The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 1998, 9, 211–219.
  22. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP: Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec cardiovascular study. Arterioscler Thromb Vasc Biol 1997, 17, 1098–1105.
  23. Kuusi T, Saarinen P, Nikkila EA: Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein 2 in man. Atherosclerosis 1980, 36, 589–593.
  24. Ko YL, Hsu LA, Hsu KH, Ko YH, Lee YS: The interactive effects of hepatic lipase gene promoter polymorphisms with sex and obesity on high-density-lipoprotein cholesterol levels in Taiwanese-Chinese. Atherosclerosis 2004, 172, 135–142.
  25. De Andrade FM, Silveira FR, Arsand M, Antunes AL, Torres MR, Zago AJ, Callegari-Jaques SM, Hutz MH: Association between –250G/A polymorphism of the hepatic lipase gene promoter and coronary artery disease and HDL-C levels in a southern Brazilian population. Clin Genet 2004, 65, 390–395.
  26. Price TM et al.: Estrogen regulation of adipose tissue lipoprotein lipase – possible mechanism of body fat distribution. Am J Obstet Gynecol 1998, 178, 101–107.
© Wroclaw Medical University